Skip to content

Impact of perindopril on mobilization of bone marrow-derived endothelial progenitor cells in type 2 diabetic patients with acute myocardial infarction and effect on prognosis

Impact of perindopril on mobilization of bone marrow-derived endothelial progenitor cells in type 2 diabetic patients with acute myocardial infarction and effect on prognosis

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12002599
Enrollment
Unknown
Registered
2012-10-17
Start date
2011-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myocardial infarction

Interventions

Two groups:perindopril vs no treatment

Sponsors

Nanjing Drum Tower Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
42 Years to 82 Years

Inclusion criteria

Inclusion criteria: participants with T2DM which diagnosed as glycated hemoglobin>=6.1 mmol/L and controlled by diet or blood glucose lowing agents were recruited. All patients were in accordance with the diagnostic criteria for AMI and received acute percutaneous coronary intervention (PCI) within 12h after onset of symptoms and followed a similar anticoagulation and medication (beta blocker, statin) regimen according to established guidelines. The criteria for AMI are as follows: 1. typical ischemic chest pain lasting for>=30min; 2. ECG changes represent as new onset ST-segment elevation >=0.1 mV in 2 or more contiguous peripheral leads, and/or >=0.2 mV in 2 or more contiguous precordial leads; 3. Evidences of myocardial injury or necrosis indicated by elevated serum cardiac biomarker including creatine kinase (CK) and/or troponin T (TnT).

Exclusion criteria

Exclusion criteria: exclusion criteria were uncontrolled hypertension or blood pressure<=100/70mmHg, using ACE inhibitors/ARB in a week or contradicting ACE inhibitors therapy, severe arrhythmia, IV level cardiac function or EF<=35%, history of renal or hepatic disorders and having other infarction disease such as pulmonary or cerebral infarction in recent days (6 months)

Design outcomes

Primary

MeasureTime frame
endothelial progenitor cell;echocardiograph;

Secondary

MeasureTime frame
VEGF;hsCRP;

Countries

China

Contacts

Public ContactXu Biao
xubiao@medmail.com.cn+86 25 8310 5205

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 23, 2026